CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications

被引：590
|
作者：
Liu, Mingli [1 ]
Guo, Shanchun [1 ]
Hibbert, Jacqueline M. [1 ]
Jain, Vidhan [2 ]
Singh, Neeru [2 ]
Wilson, Nana O. [1 ]
Stiles, Jonathan K. [1 ]
机构：
[1] Morehouse Sch Med, Dept Microbiol Biochem & Immunol, Atlanta, GA 30310 USA
[2] Natl Inst Malaria Res ICMR, Jabalpur, India
来源：
CYTOKINE & GROWTH FACTOR REVIEWS | 2011年 / 22卷 / 03期
基金：
美国国家卫生研究院;
关键词：
Chemokine; CXCL10; CXCR3; Infectious diseases; GAMMA-INDUCIBLE PROTEIN-10; CHEMOKINE RECEPTOR CXCR3; DECREASES SECONDARY DEGENERATION; MESSENGER-RNA EXPRESSION; MURINE CEREBRAL MALARIA; AIRWAY EPITHELIAL-CELLS; CENTRAL-NERVOUS-SYSTEM; IFN-GAMMA; TNF-ALPHA; PROTECTIVE IMMUNITY;
D O I：
10.1016/j.cytogfr.2011.06.001
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
C-X-C motif chemokine 10 (CXCL10) also known as interferon gamma-induced protein 10 kDa (IP-10) or small-inducible cytokine 810 is a cytokine belonging to the CXC chemokine family. CXCL I 0 binds CXCR3 receptor to induce chemotaxis, apoptosis, cell growth and angiostasis. Alterations in CXCL10 expression levels have been associated with inflammatory diseases including infectious diseases, immune dysfunction and tumor development. CXCL10 is also recognized as a biomarker that predicts severity of various diseases. A review of the emerging role of CXCL10 in pathogenesis of infectious diseases revealed diverse roles of CXCL10 in disease initiation and progression. The potential utilization of CXCL10 as a therapeutic target for infectious diseases is discussed. (C) 2011 Published by Elsevier Ltd.
引用
收藏
页码：121 / 130
页数：10
相关论文
共 50 条
  • [1] An IP-10 (CXCL10)-Derived Peptide Inhibits Angiogenesis
    Yates-Binder, Cecelia C.
    Rodgers, Margaret
    Jaynes, Jesse
    Wells, Alan
    Bodnar, Richard J.
    Turner, Timothy
    PLOS ONE, 2012, 7 (07):
  • [2] CXCL10/IP-10 Is a Biomarker and Mediator for Kawasaki Disease
    Ko, Tai-Ming
    Kuo, Ho-Chang
    Chang, Jeng-Sheng
    Chen, Shih-Ping
    Liu, Yi-Min
    Chen, Hui-Wen
    Tsai, Fuu-Jen
    Lee, Yi-Ching
    Chen, Chien-Hsiun
    Wu, Jer-Yuarn
    Chen, Yuan-Tsong
    CIRCULATION RESEARCH, 2015, 116 (05) : 876 - 883
  • [3] Inhibition of pulmonary fibrosis by the chemokine IP-10/CXCL10
    Tager, AM
    Kradin, RL
    LaCamera, P
    Bercury, SD
    Campanella, GSV
    Leary, CP
    Polosukhin, V
    Zhao, LH
    Sakamoto, H
    Blackwell, TS
    Luster, AD
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2004, 31 (04) : 395 - 404
  • [4] Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased levels of IP-10/CXCL10 in the serum of patients with recent-onset Graves' disease
    Romagnani, P
    Rotondi, M
    Lazzeri, E
    Lasagni, L
    Francalanci, M
    Buonamano, A
    Milani, S
    Vitti, P
    Chiovato, L
    Tonacchera, M
    Bellastella, A
    Serio, M
    AMERICAN JOURNAL OF PATHOLOGY, 2002, 161 (01): : 195 - 206
  • [5] Induction of IP-10 (CXCL10) in astrocytes following Japanese encephalitis
    Bhowmick, Sourojit
    Duseja, Rachna
    Das, Sulagna
    Appaiahgiri, Mohan Babu
    Vrati, Sudhanshu
    Basu, Anirban
    NEUROSCIENCE LETTERS, 2007, 414 (01) : 45 - 50
  • [6] CXCL10/IP-10, an early biomarker for late sequelae in DRESS?
    Bellon, T.
    Kardaun, S. H.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (05) : 804 - 805
  • [7] EVIDENCE FOR CXCL10 (IP-10) ANTAGONISM IN CHRONIC HCV INFECTION
    Mallet, V.
    Casrouge, A.
    Vallet-Pichard, A.
    Ahloulay, M.
    Pol, S.
    Albert, M.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S122 - S122
  • [8] Crystal structures of oligomeric forms of the IP-10/CXCL10 chemokine
    Swaminathan, GJ
    Holloway, DE
    Colvin, RA
    Campanella, GK
    Papageorgiou, AC
    Luster, AD
    Acharya, KR
    STRUCTURE, 2003, 11 (05) : 521 - 532
  • [9] Understanding the pleiotropic effects of CXCL10/IP-10 in the immunopathogenesis of inflammatory rheumatic diseases: Implications for better understanding disease mechanisms
    Rokni, Mohsen
    Khomeijani-Farahani, Mohammadreza
    Soltani, Taha
    Jamshidi, Ahmadreza
    Mahmoudi, Mahdi
    Farhadi, Elham
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2025, 153
  • [10] Significance of serum CXCL10/IP-10 level in type 1 diabetes
    Shigihara, T
    Oikawa, Y
    Kanazawa, Y
    Okubo, Y
    Narumi, S
    Saruta, T
    Shimada, A
    JOURNAL OF AUTOIMMUNITY, 2006, 26 (01) : 66 - 71
12345